Develops drugs for idiopathic pulmonary fibrosis and chronic pain.
Dec 2024Revenue $0.00/yrExpenses $50.9M/yr
Fell below break-even Mar 2024Cash runway ≈ 4.4 years from Jun 2026
Figures by year
When will Contineum Therapeutics be profitable again?
Its expenses passed its revenue in Mar 2024. In the 12 months to Dec 2024, revenue was $0.00 and expenses $50.9M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2024 | $0.00 | $50.9M | −$50.9M |
| Dec 2023 | $50.0M | $33.9M | $16.1M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.